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Introduction
Epigenetic deregulation of gene expression is increasingly recognized as fundamental for the pathogenesis of acute myeloid leukemia (AML). Although the mechanisms by which these changes contribute to leukemogenesis are still incompletely understood, the identification of mutations in several genes involved in epigenetic regulation have revealed new insights into these mechanisms. Recently, whole genome and exome sequencing led to the identification of recurrent somatic mutations in DNMT3A (encoding DNA methyltransferase 3A) in about 20% of patients with de novo AML. [1] [2] [3] DNMT3A is crucial for the methylation of unmodified DNA in CpG islands by converting cytosine to 5-methylcytosine which is associated with gene silencing. 4, 5 In vitro, enzymatic assays showed a reduction in DNA methylation by mutated DNMT3A and overexpression of the two most frequent DNMT3A mutants (R882H and R882C) promoted proliferation in cell culture experiments. 3 Of clinical importance, DNMT3A mutations were associated with decreased overall survival. 1, 3, 6 These results strongly suggest a prominent pathogenetic role of DNMT3A mutations in AML.
Although most patients are diagnosed with de novo AML, in about 20-30% of cases AML presents as a sequelae of a previous disease. This group encompasses patients, in whom AML develops after chemo-and/or radiotherapy for a primary, most often malignant disease.
Furthermore, patients suffering from myelodysplastic syndromes or myeloproliferative neoplasms (MDS/MPN) have a substantial risk of transformation to AML. Both, therapyrelated (t-AML) as well as secondary AML (sAML) following an antecedent MDS/MPN are associated with low survival rates following conventional therapy including hematopoietic stem cell transplantation. [7] [8] [9] In some cases, t-AML and sAML share common cytogenetic and molecular alterations with poor-risk de novo AML such as loss of chromosome 5 and 7. 10, 11 However, in a substantial proportion of patients genetic alterations responsible for the dismal clinical course have not been established.
To determine the frequencies, patterns and clinical impact of DNMT3A mutations in patients with t-AML and sAML, we performed mutational analysis of all coding exons of DNMT3A in a cohort of 98 patients by direct DNA sequencing. Furthermore, specimens from the antecedent haematological disorder in sAML patients with mutated DNMT3A provided insights in the onset of DNMT3A mutations and their role in leukemic transformation.
Design and methods
Patients, DNA isolation and sequencing.
Thirty-seven patients with sAML and 61 patients with t-AML were included in this study.
Diagnosis was made according to the French-American-British (FAB) classification. The majority of sAML patients had a history of antecedent MDS (n=27; refractory anemia with excess blasts (RAEB), n=10; RAEB in transformation, n=1; refractory anemia, n=16) whereas the remaining sAML patients had a history of MPN (n=10; primary myelofibrosis, n=5; essential thrombocythemia, n=1; polycythemia vera, n=1; chronic myelomonocytic leukemia, n=3 
Statistical analysis
Differences in characteristics of patients with or without DNMT3A mutations were calculated using a two-sided Fisher´s exact or Mann-Whitney tests. The Kaplan-Meier method was applied to generate the survival curves and differences were assessed by Log-Rank analysis.
Software R 2.13.0 (www.r-project.org) was used for the analyses.
Results and Discussion

Frequency and patterns of DNMT3A mutations in t-and sAML
Of 98 t-AML and sAML samples in this study, a DNMT3A mutation was identified in a total of 23 (23.6%). One patient displayed two mutations (clinical details of patients with mutations are given in Table 1 ; a comparison of clinical characteristics in DNMT3A -mutated vs. non-mutated patients is given in supplementary Table 2 ). The frequency of DNMT3A mutations in this cohort is therefore similar to patients with de novo AML, which was reported 22.1%, 1 20.5%, 3 and 17.8%. 6 However, when assessing sAML and t-AML patients of our cohort separately, the percentage of patients with a DNMT3A mutation was higher in Table 2 ).
The mutations identified in this study comprised 23 missense and one splice site mutation located upstream of exon 10 (c.1123-2 A>G; see Table 1 and supplementary Figure 1 ).
Although the hot spot mutation affecting arginine on position 882 was also the most frequent mutation in our study (3 in t-AML and 6 in sAML), the majority of mutations in DNMT3A (n=15) affected other amino acid residues (see Table 1 and supplementary Figure 1 ). This is in contrast to the findings in de novo AML, where in total of all published studies 1, 3, 6 116 out of 176 mutations were affecting R882 (p=0.01203 as compared to our cohort). These results suggest a somewhat different pattern of DNMT3A mutations in t-AML and sAML as compared to de novo AML. Since most of our identified mutations (S352N, W581C, V636M, I655A, F731C, Y735C, F752L, W753G, L754R, W795C, P849R, L889P, A910V) have not been reported previously, we tested constitutional DNA to prove the somatic nature of these mutations (see Figure 1 and supplementary Figure 1 ). In all but one case, in which we had no access to constitutional material, we were able to delineate the somatic origin of the mutations. In the remaining case, the affected amino acid is highly conserved among species and is not reported to constitute single nucleotide polymorphisms in public databases.
Mutation of the acceptor splice site resulted in the use of an alternative 3' splice site upstream thereby inserting a 40-bp intronic sequence in between exon 9 and exon 10 in the patient's mRNA (see supplementary Figure 1A , lower left panel). As a consequence, a premature stop codon is introduced that is predicted to lead to a truncated protein with 432 amino acids lacking the zinc finger and methyltransferase domains.
DNMT3A mutations occur early in MDS/MPN and reduction to homozygosity is occasionally associated with disease progression.
Two recent studies reported an incidence of 8% and 10% of DNMT3A mutations in MDS and MPN, respectively, 13,14 which is substantially lower than the percentage of mutated samples in our sAML cohort (35.1%). One explanation for this discrepancy might be the acquisition of DNMT3A mutations during MDS/MPN progression resulting in transformation to sAML. To test this hypothesis, we analyzed DNA from bone marrow biopsies at initial diagnosis of MDS/MPN in ten patients with mutated sAML samples. In all patients the corresponding mutation could already be detected at that time indicating that DNMT3A mutations are an early event in the pathogenesis of these malignancies. Interestingly, we identified one MDS patient with a heterozygous mutation that became homozygous during the progression to sAML ( Figure 1B, upper panel) . Another patient, who was still heterozygous for the mutation at sAML diagnosis displayed homozygosity for the mutation at the time of sAML relapse after autologous stem cell transplantation ( Figure 1B, lower panel) . Remarkably, this patient also showed a homozygous IDH2 mutation at relapse of the sAML, which was recently reported by our group. 12 These results indicate that in some MDS/MPN patients progression of disease is associated with the loss of the DNMT3A wildtype allele.
Two patients with t-AML also showed a homozygous DNMT3A mutation ( Figure 1A ), which -together with the two sAML patients -is a substantial number considering that homozygous DNMT3A mutations have been rarely documented in AML. 1, 3 To reveal the mechanisms leading to homozygosity of mutant DNMT3A , we performed copy-number variation analysis and heterozygosity mapping in all four patients using Affymetrix human genome-wide SNP 6.0 arrays. We detected a copy-neutral loss of heterozygosity of 2p23.3-2pter in both sAML patients and a copy-neutral loss of heterozygosity of 2p11-2pter in both t-AML patients ( Figure 1C ). Since the DNMT3A gene is located on 2p23.3, these results implicate uniparental disomy (UPD) of the region carrying the mutated DNMT3A allele in all these patients. Except for the patient who also showed a homozygous IDH2 mutation and UPD of the involved region on 15q as well as a deletion of 7q, 14 UPD of 2p was the only detected aberration in the remaining three patients using SNP array analysis.
Clinical impact of DNMT3A mutations in t-AML and sAML
In de novo AML, DNMT3A mutations are associated with an adverse prognosis. 1, 3, 6 However, while uni-and multivariate analysis identified well-known risk factors for poor survival in our cohort, such as cytogenetic risk and white blood cell counts at AML diagnosis, the presence of DNMT3A mutations did not affect overall survival in t-AML and sAML patients (Figure 2A and 2B ). Since t-AML and sAML are known to be associated with poor survival as compared to de novo AML and many of these patients display poor-risk cytogenetics, it may not be surprising that DNMT3A mutations do not further add to the poor prognosis in this cohort of patients. Mutated patients showed a shorter interval between MDS/MPN diagnosis and transformation to sAML (median time to progression 7.5 vs. 12 months), which is in accordance with findings of Walter et al. who reported on a more rapid progression to AML in MDS patients with DNMT3A mutations. 13 However, in our cohort the difference was not statistically significant (p=0.17).
In summary, this study demonstrated DMNT3A mutations in about one sixth of patients with t-AML. In sAML, even one out of three patients was carrying a mutation in DNMT3A . The respective mutations occurred early in the myelodysplastic or myeloproliferative phase of the disease and reduction to homozygosity by uniparental disomy of the genetic region involved was found in some patients during disease progression. DNMT3A mutations did not constitute an additional adverse risk factor in these poor prognostic subtypes of AML. * Full data on treatment were available in 82 patients. Patients with standard therapy received at least one cycle of induction chemotherapy with an anthracycline and cytarabine, whereas patients with palliative treatment either received low-dose cytarabine, hydroxyurea, azacytidine or best supportive care. Patients who underwent allogeneic hematopoietic stem cell transplantation for consolidation were counted in the standard treatment group also.
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